BCYC — Bicycle Therapeutics Ltd
NASDAQ · Healthcare · Biotechnology
$4.22
+$0.13 (+3.05%)
Bicycle Therapeutics Ltd (BCYC) is a biotechnology company listed on NASDAQ. It is led by Kevin Lee M.B.A., Ph.D., based in Portway Building, Cambridge, United Kingdom, CB21 6GS, with about 305 employees. Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; and Genentech, Inc. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Latest reported BCYC revenue for 2025-09-30 was $11.7M. Net income was -$198.8M. Revenue was up 301.8% from 2025-06-30 to 2025-09-30. BCYC currently screens at market cap $554.0M.
Use this BCYC page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BCYC quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BCYC SEC filings page. Lician reads the product cache first so this HTML stays unique to Bicycle Therapeutics Ltd even when a live quote feed is slow.
About Bicycle Therapeutics Ltd
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; and Genentech, Inc. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
BCYC Key Statistics
Market Cap
$554.03M
Volume
166,144
Previous Close
$4.39
Day Range
$4.28 – $4.41
EPS
-$2.90
Revenue
$35.27M
Net Income
-$169.03M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+30.8%
Profit Margin
-479.2%
Employees
305
BCYC Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $35.27M | $26.98M | $14.46M | $11.70M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$169.03M | -$180.66M | -$112.72M | -$66.82M |
| EPS (Diluted) | -$2.90 | -$5.08 | -$3.80 | -$2.67 |
Total Assets
$956.87M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$879.52M
Operating Cash Flow
-$164.72M
Free Cash Flow
$0.00
Bicycle Therapeutics Ltd Company Information
- CEO & Executive Director
- Kevin Lee M.B.A., Ph.D.
- Headquarters
- Portway Building, Cambridge, United Kingdom, CB21 6GS
- Website
- www.bicycletherapeutics.com
- Phone
- 44 1223 261 503
- IPO / Founded
- 2019-05-23
- Sector
- Healthcare
- Industry
- Biotechnology